SHANGHAI – For a small start-up with only two and a half years under its belt, Suzhou Connect Biopharmaceuticals Inc., of Suzhou, Jiangsu, is understandably pleased to be kicking off its phase I trials for CBP-307 in Australia. Developed in-house, CBP-307 is a second-generation S1P1 modulator with the potential to treat autoimmune disorders such as multiple sclerosis (MS), psoriasis or inflammatory bowel disease.